secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2026-06-11T20:52:12+00:00
Accession:  0001746473-26-000092
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics annual meeting approves all proposals; say-on-pay passes with narrow margin
--------------------------------------------------------------------------------

- Elected Class III directors Coulie, Crowell, and Krognes with 18.8M, 18.2M, and 19.3M votes for respectively.
- Advisory vote on executive compensation approved: 15.3M for, 14.6M against, 0.8M abstain; 11.9M broker non-votes.
- Ratification of Deloitte as independent auditor for FY2026 passed with 41.7M for, 0.7M against, 69K abstain.
- Approximately 61.9M shares outstanding; broker non-votes totaled 11.9M on director and say-on-pay proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000092/0001746473-26-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000092/plrx-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001746473-26-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer